EXCLUSIVE LIFE SCIENCE FEATURE
leaders
LIFESCIENCELEADER.COM OCTOBER 2014
24
BIOGEN
IDEC'S
STRATEGY
FOR
NEUROLOGY
R&D;
SUCCESS
By
R.
Wright
BIOGEN IDEC
'
S
WHEN IT COMES TO THE BUSINESS OF NEUROLOGIC
DRUG DISCOVERY AND DEVELOPMENT, INVESTORS
SEEK INSPIRATION IN RESULTS — WHICH HISTORY HAS
SHOWN TO BE A TALL TASK. For example, this past July,
researchers at the Cleveland Clinic Lou Ruvo Center for Brain
Health concluded that of the 244 drugs tested for Alzheimer's
disease (AD) from 2002-2012, only one was a success. This
rather sobering statistic doesn't scare the oldest independent
biotechnology company in the world, Biogen Idec (NASDAQ:
BIIB), from taking on neurological monsters like AD, or even
amyotrophic lateral sclerosis (ALS) or Parkinson's disease.
STRATEGY
FOR NEUROLOGY
R&D; SUCCESS
R O B W R I G H T Chief Editor